1. Home
  2. RSSS vs ELTX Comparison

RSSS vs ELTX Comparison

Compare RSSS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.15

Market Cap

72.9M

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSSS
ELTX
Founded
2006
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.9M
63.3M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
RSSS
ELTX
Price
$2.15
$1.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$18.00
AVG Volume (30 Days)
44.9K
328.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
125.00
39.29
EPS
0.09
N/A
Revenue
$28,793,922.00
$2,301,000.00
Revenue This Year
$1.81
N/A
Revenue Next Year
$5.73
N/A
P/E Ratio
$23.11
N/A
Revenue Growth
2.77
N/A
52 Week Low
$1.92
$1.71
52 Week High
$4.12
$16.00

Technical Indicators

Market Signals
Indicator
RSSS
ELTX
Relative Strength Index (RSI) 46.93 29.02
Support Level $2.00 N/A
Resistance Level $2.36 $3.32
Average True Range (ATR) 0.09 0.14
MACD -0.01 -0.01
Stochastic Oscillator 57.14 26.87

Price Performance

Historical Comparison
RSSS
ELTX

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: